National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Adult Soft Tissue Sarcoma Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 07/25/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information







Stage I Adult Soft Tissue Sarcoma






Stage II and III Adult Soft Tissue Sarcoma






Stage IV Adult Soft Tissue Sarcoma






Recurrent Adult Soft Tissue Sarcoma






Get More Information From NCI






Changes to This Summary (07/25/2008)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
The Cancer Genome Atlas Reports Brain Tumors Study

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Stage I Adult Soft Tissue Sarcoma

Current Clinical Trials

Low-grade soft tissue sarcomas (grade 1 or 2) have little metastatic potential, but they may recur locally if they are inadequately treated. Accordingly, surgical excision with negative tissue margins of 2 cm or larger in all directions is the treatment of choice for patients with these early-stage sarcomas.[1] Mohs surgical technique may be considered as an alternative to wide surgical excision for small, well-differentiated sarcomas when cosmetic results are considered to be very important, as margins can be assured with minimal normal tissue removal.[2,3]

Carefully executed high-dose radiation therapy using a shrinking field technique may be beneficial for unresectable tumors or for resectable tumors in which a high likelihood of residual disease is thought to be present, when margins are known to be smaller than 2 cm, and when wider resection would require either an amputation or the removal of a vital organ.[4] Because of the low metastatic potential of these tumors, chemotherapy is usually not given.[5]

Standard treatment options:

  1. Surgical excision with negative tissue margins of several centimeters in all directions.
  2. Conservative surgical excision with preoperative or postoperative radiation therapy.[6,7]
  3. If the tumor is unresectable, high-dose preoperative radiation therapy may be used, followed by surgical resection and postoperative radiation therapy.[4,8]
  4. For tumors of the retroperitoneum, trunk, and head and neck:
    • Surgical resection with the option of postoperative radiation therapy if negative margins cannot be obtained. Wide margins are unusual in these sites, and radiation therapy is usually advocated for trunk and head and neck primary sites.[3]
    • Preoperative radiation therapy followed by maximal surgical resection. Radiation therapy is usually used to maximize local control because of the inability to obtain wide surgical margins.
    • Fast neutron therapy.[9]
Current Clinical Trials

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with stage I adult soft tissue sarcoma. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI Web site.

References

  1. Pearlstone DB, Pisters PW, Bold RJ, et al.: Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer 85 (1): 85-92, 1999.  [PUBMED Abstract]

  2. Fish FS: Soft tissue sarcomas in dermatology. Dermatol Surg 22 (3): 268-73, 1996.  [PUBMED Abstract]

  3. Brennan M, Singer S, Maki R, et al.: Sarcomas of the soft tissues and bone. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2005, pp 1581-1631. 

  4. Temple WJ, Temple CL, Arthur K, et al.: Prospective cohort study of neoadjuvant treatment in conservative surgery of soft tissue sarcomas. Ann Surg Oncol 4 (7): 586-90, 1997 Oct-Nov.  [PUBMED Abstract]

  5. Geer RJ, Woodruff J, Casper ES, et al.: Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg 127 (11): 1285-9, 1992.  [PUBMED Abstract]

  6. Tepper JE, Suit HD: Radiation therapy of soft tissue sarcomas. Cancer 55 (9 Suppl): 2273-7, 1985.  [PUBMED Abstract]

  7. Yang JC, Chang AE, Baker AR, et al.: Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16 (1): 197-203, 1998.  [PUBMED Abstract]

  8. Schmidt RA, Conrad EU 3rd, Collins C, et al.: Measurement and prediction of the short-term response of soft tissue sarcomas to chemotherapy. Cancer 72 (9): 2593-601, 1993.  [PUBMED Abstract]

  9. Schwartz DL, Einck J, Bellon J, et al.: Fast neutron radiotherapy for soft tissue and cartilaginous sarcomas at high risk for local recurrence. Int J Radiat Oncol Biol Phys 50 (2): 449-56, 2001 Jun 1.  [PUBMED Abstract]

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov